All Phenotypes Ranbp2<tm1.1Jvd> MGI Mouse

Phenotypes associated with this allele

Jump to	Allelic Composition	Genetic Background	Genotype ID
hm1	Ranbp2^tm1.1Jvd/Ranbp2^tm1.1Jvd	involves: 129/Sv * C57BL/6	MGI:3802797
ht2	Ranbp2^tm1.1Jvd/Ranbp2⁺	involves: 129/Sv * C57BL/6	MGI:3802799
ht3	Ranbp2^tm1Jvd/Ranbp2^tm1.1Jvd	involves: 129/Sv * C57BL/6	MGI:3802800

Allelic Composition	Ranbp2^tm1.1Jvd/Ranbp2^tm1.1Jvd
Genetic Background	involves: 129/Sv * C57BL/6

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ranbp2^tm1.1Jvd mutation (0 available); any Ranbp2 mutation (115 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

mortality/aging

embryonic lethality, complete penetrance ( J:137482 )

• death prior to E13.5

Allelic Composition	Ranbp2^tm1.1Jvd/Ranbp2⁺
Genetic Background	involves: 129/Sv * C57BL/6

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ranbp2^tm1.1Jvd mutation (0 available); any Ranbp2 mutation (115 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

cellular

aneuploidy ( J:137482 )

• in about 1% of splenocytes

• also range of aneuploidy broadened

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

cellular

aneuploidy ( J:137482 )

• in about 15% of splenocytes

• also range of aneuploidy broadened

abnormal mitosis ( J:137482 )

• 9% of splenocytes fail to progress from metaphase to anaphase

elevated level of mitotic sister chromatid exchange ( J:137482 )

• in cells in which mitosis proceeds, 30% form chromatin bridges

• small number of cells with more than two bridges between chromosomes

• bridges resolve during telophase or cytokinesis

• no evidence for increased chromosome breakage or end-end fusions

neoplasm

increased tumor incidence ( J:137482 )

• increased incidence of spontaneous tumor development

increased incidence of tumors by chemical induction ( J:137482 )

• dramatic increase in skin tumors within 5 months of treatment with DMBA

• 100% of mice with lung tumors within 5 months of treatment with DMBA

• elevated tumor burden (14/mouse) in mice treated with DMBA

increased hepatocellular carcinoma incidence ( J:137482 )

increased lung carcinoma incidence ( J:137482 )

increased sarcoma incidence ( J:137482 )

decreased tumor latency ( J:137482 )

• shorter latency for spontaneous tumor development

homeostasis/metabolism